Exploiting AR-Synergistic Metabolic Vulnerabilities in Prostate Cancer.

Resistance to androgen deprivation therapy remains a major clinical challenge in prostate cancer, necessitating alternative therapeutic strategies. The androgen receptor (AR) plays a central role in driving resistance through mechanisms including enh…

Preview only. Read the full abstract at the source